.png)
In the world of drug discovery, innovation is key. Yet a closer look at industry trends uncovers an intriguing narrative within the pharmaceutical sector.
A growing amount of M&A activity in healthcare suggests that the pharmaceutical industry is prioritizing acquisitions over traditional research & development. The fourth quarter of 2023 alone saw a remarkable 426 M&A deals in this sector. Is this shift in strategy an ingenious response to the evolving demands of the industry, or yet another way to secure the standing of the world’s largest pharmaceutical companies?
The global pharmaceutical sector has around $700 billion USD at its disposal for acquisitions, research, and development, according to a recent report by Goldman Sachs. The key question is where that’s going to go.
Given the pharmaceutical industry is in tremendous need for growth and is sitting on a hefty amount of cash, acquisitions seem most practical.
M&A Activity of 12 of the Largest Pharmaceutical Companies
Research & Development (R&D) is the engine of innovation in the pharmaceutical sector. It’s within the labs of companies that groundbreaking treatments are often discovered, cures are conceived, and drugs are developed. However, various factors have helped contribute to the growing complexity of R&D, including escalating costs, delays in clinical development, and patent expirations of existing pipelines, prompting many companies to think outside the box.
The primary appeal for an acquisition is the immediate access to a portfolio of therapies that have already undergone significant scientific development, thereby bypassing the lengthy R&D process, utilizing existing clinical network relationships, and accelerating the time to market and revenue generation. This access to established assets is a remarkable opportunity for the pharma sector, and coupled with the mitigated risk and diversification potential, is a highly lucrative business model.
Further, the parent company is often able to dedicate financial resources, existing market access and distribution channels, regulatory expertise, operational scale, and strategic leadership, accelerating the drug development process.
Pfizer: A Case Study
Pfizer’s acquisition of Warner Lambert in 2000 remains the most valuable M&A transaction in healthcare to this day. For nearly $90 billion USD, Pfizer’s acquisition helped it claim the title as the world’s second-largest drug company, at the time, and full shares of profits from key drugs, including Lipitor, a high cholesterol statin that continues to generate over $2 billion USD annually in sales, even following patent expiration.
More recently, Pfizer acquired Wyeth for roughly $70 billion USD, helping Pfizer diversify its pipeline in Alzheimer’s, inflammation, and oncology.
In its own words, Pfizer reported, “The combined company will have product offerings in numerous growing therapeutic areas, a strong product pipeline, leading scientific and manufacturing capabilities, and a premier global footprint in health care.”
In both of these cases, Pfizer leveraged the target company’s existing, patent-protected pipelines to diversify and grow its own pipeline, while mitigating the risk of researching drugs that might not work.
The overemphasis on acquisitions, however, raises key questions and ethical concerns regarding access to essential medicines and healthcare disparities. Pharmaceutical companies, now more than ever, have a moral imperative that transcends profit margins: to prioritize more affordable and accessible treatments.
Large companies that acquire and control a significant share of a given market wield immense power to dictate prices and control access, undermining consumer choice and deterring potential competition. Further, the process discourages the development of generic alternatives.
Following an acquisition, companies often file for patent extensions and engage in patent litigation to delay generic entry, often accomplished through settlements with the generic manufacturer. Companies also use many strategies to extend the protection of their patents and prolonging their market exclusivity, including:
Minor modifications to existing approved drugs (Patent Evergreening)
Filing for additional patents covering different aspects of the medication
Secondary patents covering the active ingredient, dosing regimens, methods of administration, or secondary formulations
Drugs treating rare diseases or pediatric diseases are given extended exclusivity
Consequently, the growing number of acquisitions is raising concerns at the federal level, particularly around antitrust. Given that maintaining competition in the pharmaceutical industry is directly associated with controlling healthcare costs and innovation, M&A in pharma is a critical issue for policymakers, researchers, hospitals, and patients globally.
Learn more about Mergers, Acquisitions, and protecting consumers in the healthcare sector and see the Federal Trade Commissions's statement on M&A here.
©️ Copyright 2024
Legal Disclaimer:
The information provided in this article has been collected from various academic publications, industry reports/analyses, regulatory guidelines, media coverage, and legal analyses. The information provided is for general information purposes only and should not be construed for medical, legal, financial, or professional advice. Readers are advised to seek independent professional guidance where relevant. While we strive to ensure the accuracy and timeliness of our coverage, we claim no liability, representations, or warranties of any kind about the completeness, suitability, accuracy, reliability or availability of this article and all pertaining data within this article. Neither the author nor the publication will assume liability for any loss or damage arising from the use of the information provided in the article. The information within this article may be outdated or inaccurate over time, and neither the author nor the publication are obligated to update or revise such information. We reserve the right to modify, remove, or substantially edit the article, including the disclaimer, at any time.
